课题基金 / 基金详情

项目摘要

项目成果

Kanta Subbarao的其他基金

相似基金

相关文献

中文摘要
翻译
适当的疫苗对于全球大流行的防备和应对至关重要。血凝抑制试验显示,2009年大流行的H1N1病毒在抗原性上是同质的,与目前流行的季节性H1N1病毒不同。根据抗原性和基因分析以及流行病学资料,世界卫生组织选择A/California/7/2009(H1N1)病毒作为疫苗开发的参考病毒。我们将在临床试验中评估含有加利福尼亚/7/2009(H1N1)病毒表面糖蛋白和A/Ann Arbor/6/60冷适应(CA)病毒内部蛋白基因的H1N1减毒活病毒的免疫原性和感染性。
英文摘要
An appropriate vaccine is essential for a global pandemic preparedness and response. Hemagglutination inhibition assays reveal that the 2009 pandemic H1N1 viruses are antigenically homogeneous and distinct from currently circulating seasonal H1N1 viruses. Based on antigenic and genetic analysis and epidemiologic information, the WHO selected the A/California/7/2009 (H1N1) virus as the reference virus for vaccine development. We will evaluate the immunogenicity and infectivity of the live attenuated reassortant H1N1 virus containing the surface glycoproteins from the California/7/2009 (H1N1) virus and internal protein genes from the A/Ann Arbor/6/60 cold-adapted (ca) virus in clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EVAL. OF VACCINE AGAINST HIGHLY PATHOGENIC INFLUENZA A(H5N1) VIRUS IN MACAQUES
Vaccines for Pandemic Influenza
Preclinical Studies of Vaccines for Pandemic Influenza
Clinical Studies of Vaccines for Pandemic Influenza
海外基金